Home/Filings/4/0000950170-24-135521
4//SEC Filing

KAKKIS EMIL D 4

Accession 0000950170-24-135521

CIK 0001515673other

Filed

Dec 10, 7:00 PM ET

Accepted

Dec 11, 6:44 PM ET

Size

7.1 KB

Accession

0000950170-24-135521

Insider Transaction Report

Form 4
Period: 2024-12-09
KAKKIS EMIL D
DirectorPresident & CEO10% Owner
Transactions
  • Gift

    Common Stock

    2024-12-0920,0002,203,985 total(indirect: By Trust)
  • Sale

    Common Stock

    2024-12-10$50.00/sh8,273$413,6502,195,712 total(indirect: By Trust)
Holdings
  • Common Stock

    564,605
Footnotes (2)
  • [F1]Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
  • [F2]Includes 8 shares acquired under the Company's A&R 2014 Employee Stock Purchase Plan on October 31, 2024.

Documents

1 file

Issuer

Ultragenyx Pharmaceutical Inc.

CIK 0001515673

Entity typeother

Related Parties

1
  • filerCIK 0001248093

Filing Metadata

Form type
4
Filed
Dec 10, 7:00 PM ET
Accepted
Dec 11, 6:44 PM ET
Size
7.1 KB